Head to Head Analysis: Opiant Pharmaceuticals (OPNT) vs. Baxalta (BXLT)

Opiant Pharmaceuticals (NASDAQ: OPNT) and Baxalta (NYSE:BXLT) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Earnings and Valuation

This table compares Opiant Pharmaceuticals and Baxalta’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Opiant Pharmaceuticals $18.45 million 2.81 $6.58 million ($1.41) -14.48
Baxalta N/A N/A N/A $1.19 N/A

Opiant Pharmaceuticals has higher revenue and earnings than Baxalta. Opiant Pharmaceuticals is trading at a lower price-to-earnings ratio than Baxalta, indicating that it is currently the more affordable of the two stocks.


This table compares Opiant Pharmaceuticals and Baxalta’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Opiant Pharmaceuticals 8.93% 42.44% 15.34%
Baxalta 9.37% 14.28% 4.62%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Opiant Pharmaceuticals and Baxalta, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Opiant Pharmaceuticals 0 0 0 0 N/A
Baxalta 0 0 0 0 N/A

Institutional and Insider Ownership

4.7% of Opiant Pharmaceuticals shares are owned by institutional investors. 63.8% of Opiant Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.


Baxalta pays an annual dividend of $0.28 per share. Opiant Pharmaceuticals does not pay a dividend. Baxalta pays out 23.5% of its earnings in the form of a dividend. Opiant Pharmaceuticals has increased its dividend for 2 consecutive years.


Opiant Pharmaceuticals beats Baxalta on 7 of the 10 factors compared between the two stocks.

About Opiant Pharmaceuticals

Opiant Pharmaceuticals, Inc., formerly Lightlake Therapeutics, Inc., is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA). The Company’s pipeline of product candidates includes a treatment for Binge Eating Disorder (BED), a treatment for Bulimia Nervosa (BN), a treatment for Cocaine Use Disorder (CocUD) and a heroin vaccine. The Company also is focused on other treatment opportunities.

About Baxalta

Baxalta Incorporated (Baxalta) is a biopharmaceutical company with a portfolio of differentiated therapies that seek to address medical needs across various disease areas, including hemophilia, immunology and oncology. Baxalta’s categories of products include Hemophilia products, such as Advate, Adynovate, Recombinate, Hemofil M, Immunate, Immunine, Rixubis and Prothromplex Total; Inhibitor Therapies products, including FEIBA and OBIZUR; Immunoglobulin Therapies products, which include GAMMAGARD LIQUID/KIOVIG, HYQVIA, GAMMAGARD S/D and SUBCUVIA; BioTherapeutics products, including FLEXBUMIN, BUMINATE, ARALAST NP, GLASSIA NP and CEPROTIN, and Oncology product, such as ONCASPAR. Baxalta Company develops, manufactures and markets a portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions, as well as oncology treatments for acute lymphoblastic leukemia.

Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply